Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
Paola Magnaghi(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Josh Sommer(Chordoma Foundation), Dario Ballinari(Nerviano Medical Sciences), Barbara Salom(Nerviano Medical Sciences), Roberta Bosotti(Human Technopole), Laura Raddrizzani(Nerviano Medical Sciences), Christian Orrenius(Nerviano Medical Sciences), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Fabio Bozzi(Fondazione IRCCS Istituto Nazionale dei Tumori), Fabio Gasparri(Nerviano Medical Sciences), Liviana Cozzi(Nerviano Medical Sciences), Elena Tamborini(National Cancer Institute), Silvana Pilotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Arturo Galvani(Nerviano Medical Sciences), Alessio Somaschini(Nerviano Medical Sciences), Alessia Montagnoli(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 93
Related Papers
Isolation and <i>In vitro</i> Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties
|Cancer Research|2005|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853